PHARMACOVIGILANCE IN CLINICAL RESEARCH: PAST, PRESENT AND FUTURE
Journal Title: International Journal of Drug Regulatory Affairs - Year 2016, Vol 4, Issue 4
Abstract
The growing clinical research after the product patents rights for the pharmaceutical industries as per the trade related aspects of intellectual property rights agreement and adverse drug reaction monitoring of the marketed drugs have raised many ethical and regulatory issues regarding the promotion of new drugs in Indian markets. It becomes vital to understand the history, growth and evolution of the regulatory aspects of drugs which are handled by multiple Ministries and Departments of the Government of India. Although amendment to Schedule Y, registration of Ethics committee, registration of Clinical Trials, Speeding up review process, Pharmacovigilance (PhV) programme for India and Inspection of clinical trial sites have been started by the various regulatory agencies. India’s growing partaking in multinational trials, this artifact explores potential areas of Indian pharmacovigilance, requiring reform and provides recommendations for building a robust safety reporting system. (1) Despite global focus on Development Safety Update Report, local regulators are not yet insistent on real-time update of a drug's cumulative safety profile. Issues like reporting requirements for generic trials, pregnancy reporting and lenient timeline for death/life-threatening events need attention. (2)
Authors and Affiliations
Chauhan Pratibha, Yadav Ashish, Kirodian Babita
Keywords
Related Articles
- EP ID EP337075
- DOI 10.22270/ijdra.v4i4.188
- Views 93
- Downloads 0
Regulatory overview of biosimilars in Europe
A biosimilar is a biological medicine similar, but not identical, to an already registered reference bio therapeutic product in terms of quality, safety, and efficacy. These drugs are also called as biosimilar products„,...
Comparative Study of Triglyceride Level in Ischemic Heart Disease Patients in different age groups of Patients in south east Rajasthan
Backgrounds: Elevated body triglycerides have been implicated as a risk factor of ischemic heart disease (IHD). Objectives: To study the association of serum triglyceride with ischemic heart disease and to assess the rel...
INDONESIAN PATENT SYSTEM: AN OVERVIEW
Intellectual property protection is a one type of protection to the innovator from their creative efforts. On November 1, 1991, the Indonesian Parliament passed Law No. 6/1989 on Patents. The new law came into effect on...
COMPARATIVE STUDY OF REGULATORY REQUIREMENTS AND REGISTRATION PROCESS OF GENERIC DRUGS IN JAPAN AND CHINA
A Generic Product must meet the standards established by Pharmaceutical Medical Device Agency (PMDA) & China Food and Drug Administration (CFDA) to be approved for marketing in Japan and China respectively. This study co...
REGULATORY ROADMAP FOR NANOTECHNOLOGY BASED MEDICINES
Nanotechnology is emerging as one of the key technologies of the 21st century and is expected to enable developments across a wide range of sectors that can benefit citizens. Nanomedicine is an application of nanotechnol...